GlassScriptPhysician profile
Gopika Banker
NPI 1649460189
$10,532.55
in general payments reported to CMS, 2019-2025
36 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $578 · 2021: $1,912 · 2022: $1,325 · 2023: $1,008 · 2024: $3,782 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,911 · Consulting Fee: $2,700 · Education: $29.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.19 |
| Consulting Fee | $2,700.00 |
| Education | $29.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,850.33 | 2021-2024 | |
| Vifor Pharma, INC. | $1,159.97 | 2019-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $704.79 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $664.04 | 2019-2025 | Rayaldee |
| Bard Peripheral Vascular, INC. | $622.88 | 2019-2024 | Covera |
| Astrazeneca Pharmaceuticals LP | $581.36 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $539.70 | 2019-2025 | Jynarque, Voyxact |
| Akebia Therapeutics INC | $433.55 | 2019-2024 | Auryxia |
| Fresenius USA Marketing, INC. | $418.86 | 2019-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $321.74 | 2021-2024 | Lupkynis |
| Daiichi Sankyo INC. | $313.47 | 2019-2025 | Injectafer |
| Glaxosmithkline, LLC. | $297.89 | 2021-2023 | Jesduvroq |
| Calliditas Therapeutics US INC. | $191.66 | 2022-2025 | Tarpeyo |
| Amgen INC. | $175.00 | 2020-2025 | Tavneos, Krystexxa, Parsabiv |
| Medtronic, INC. | $155.63 | 2025 | Ellipsys Vascular Access System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $149.42 | 2023 | |
| Ardelyx, INC. | $130.25 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $97.85 | 2021-2025 | |
| Travere Therapeutics, INC. | $90.44 | 2019-2025 | Thiola |
| Nxstage Medical, INC. | $79.44 | 2020-2024 | |
| Xeris Pharmaceuticals, INC. | $71.21 | 2021-2023 | Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.03 | 2023-2024 | Jardiance |
| Strongbridge US INC. | $50.92 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $48.52 | 2019-2022 | |
| Horizon Therapeutics Plc | $43.74 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $42.19 | 2019 | |
| Ani Pharmaceuticals, INC. | $40.92 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $34.35 | 2024 | Rivfloza |
| Mallinckrodt Hospital Products INC. | $33.25 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $23.05 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.95 | 2025 | |
| Ascendis Pharma Endocrinology INC | $18.19 | 2025 | Yorvipath |
| Amag Pharmaceuticals, INC. | $16.17 | 2021 | |
| Shire North American Group INC | $14.97 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopika Banker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.